Abstract

Get full access to this article
View all access options for this article.
References
1.Association of British Neurologists . Revised Guidelines for Prescribing in Multiple Sclerosis . Association of British Neurologists , 2009 .
2.EMEA guidelines on natalizumab .
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000603/WC500044690.pdf
(accessed April 2012 ).
3.
Hirst
C
Ingram
G
Pearson
O
Pickersgill
T
Scolding
N
Robertson
N
. Contribution of relapses to disability in multiple sclerosis . J Neurol
2008 ; 255 : 280 –287 .
4.
Lublin
FD
Baier
M
Cutter
G
. Effect of relapses on development of residual deficit in multiple sclerosis . Neurology
2003 ; 61 : 1528 –1532 .
5.
Skoog
B
Runmarker
B
Winblad
S
Ekholm
S
Andersen
O
. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy . Brain
2012 ; 135 : 900 –911 .
